Back to search
HR 1266 - 119

Combating Illicit Xylazine Act

Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 623.

Bill highlights

Votes, text signals, source context, and latest movement from this record.

Bill Text Stats

11
Analyzed sections
N/A
Detected dollar total
0
Tax signals
2
Deadlines

Signal counts

Tax density 0.0%
Spending density 0.0%
Statutory Reference 13
Amendments 4
Agency 3
Deadline 2
Enforcement 1
Studies 1

Top agencies

Administrator of the Drug Enforcement Administration and in 2
Commission shall 1

Statutory references

21 U.S.C. 812 3
21 U.S.C. 801 2
21 U.S.C. 802 2
21 U.S.C. 355 1
21 U.S.C. 802 1
21 U.S.C. 812 1
21 U.S.C. 827 1
21 U.S.C. 841 1

House Votes

No House roll call votes have been linked to this bill yet.

Timeline

Sep 16, 2026

Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 623.

Sep 15, 2026

Mr. Guthrie moved to suspend the rules and pass the bill, as amended.

Sep 15, 2026

Considered under suspension of the rules. (consideration: CR H5671-5673)

Sep 15, 2026

DEBATE - The House proceeded with forty minutes of debate on H.R. 1266.

Sep 15, 2026

Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.

Sep 15, 2026

On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5671-5672)

Sep 15, 2026

Motion to reconsider laid on the table Agreed to without objection.

Sep 14, 2026

Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-816, Part I.

Sep 14, 2026

Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-816, Part I.

Sep 14, 2026

Committee on the Judiciary discharged.

Sep 14, 2026

Committee on the Judiciary discharged.

Sep 14, 2026

Placed on the Union Calendar, Calendar No. 715.

Jul 21, 2026

Committee Consideration and Mark-up Session Held

Jul 21, 2026

Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 48 - 0.

Jul 20, 2026

Committee Consideration and Mark-up Session Held

Jun 25, 2026

Subcommittee Consideration and Mark-up Session Held

Jun 25, 2026

Forwarded by Subcommittee to Full Committee by Voice Vote.

Feb 12, 2025

Introduced in House

Feb 12, 2025

Introduced in House

Feb 12, 2025

Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Feb 12, 2025

Referred to the Subcommittee on Health.

Affected Sectors

How to read this

Sectors are deterministic matches from official Congress.gov data and cached bill text. They are source-derived signals, not conclusions about intent or economic effect.

Evidence matches count official fields, normalized subjects, cached text snippets, or extracted entities that matched the sector rules.

Impact is a bill-level rollup used for sorting and filtering. It is not an economic impact estimate.

Confidence is the strongest individual match score behind that sector.

Evidence snippets show why a sector matched and can repeat when Congress.gov repeats the same phrase across official fields.

Healthcare
66 evidence matches
Impact 100% Confidence 80%

Drug trafficking and controlled substances

Drug safety, medical device, and laboratory regulation

Administrator of the Drug Enforcement Administration and in administrator of the drug enforcement administration and in

Energy
1 evidence matches
Impact 91% Confidence 85%

Energy and Commerce Committee Standing House

CBO Cost Estimates

Official Congressional Budget Office cost estimate links associated with this bill through Congress.gov records.

How to read this

CBO estimates are official source documents with their own assumptions, scope, and publication dates. They can score a bill, a version of a bill, or a broader legislative package.

LawLinter stores the source link from Congress.gov and does not replace the CBO document. Use these cards as pointers for source review, not as independent fiscal advice.

CBO context shows source-attributed Congressional Budget Office cost estimates linked from official Congress.gov bill records. It is research context only; read the official CBO source document for assumptions, scope, and dates.

No CBO cost estimate is currently linked for this bill.

Campaign Finance Context

Related FEC/OpenFEC campaign-finance records for lawmakers and candidates tied to this bill through source-attributed legislative relationships. These are not donations to the bill itself.

How to read this

Amounts shown here are campaign-finance totals for sponsor or cosponsor-linked candidates and their committees in the displayed FEC cycle.

They are not donations to this bill, spending on this bill, or proof that money influenced or caused sponsorship, cosponsorship, votes, or legislative outcomes.

If multiple linked lawmakers have FEC records, this section can show multiple candidate cards and separate sponsor/cosponsor rollups.

Campaign-finance context uses source-attributed FEC/OpenFEC records that are related or relevant to the displayed bill, lawmaker, candidate, committee, or legislative relationship through deterministic links. It is research context only, not proof of influence, causation, endorsement, or that money caused a sponsorship, vote, or legislative outcome.

No FEC/OpenFEC campaign-finance context is currently linked for this bill.

Lobbying Context

Related LDA.gov filings where public lobbying activity descriptions reference this bill. These records are source-attributed research context, not evidence of influence or causation.

How to read this

LDA filings are public lobbying disclosure records. LawLinter links them here only when the filing activity text contains an exact-looking reference to this bill.

A filing can mention many issues, clients, agencies, or bills. A match should be treated as a pointer for review, not as a conclusion about why legislation changed or how any lawmaker acted.

Lobbying context uses source-attributed LDA.gov records that appear related to this bill through bill references in public lobbying activity descriptions. It is research context only, not proof of influence, causation, endorsement, lobbying effectiveness, or legislative intent.

No LDA.gov lobbying disclosure context is currently linked for this bill.

Summary

00 Introduced in House Aug 27, 2026

Combating Illicit Xylazine Act This bill regulates xylazine under the Controlled Substances Act (CSA). Xylazine, also known as tranq, is a nonopioid sedative and pain reliever that is approved for use in animals. Recently, the Drug Enforcement Administration (DEA) has reported an increase in trafficking of fentanyl mixed with xylazine. This bill adds xylazine, including its salts, isomers, and salts of isomers, to schedule III of the CSA. Schedule III controlled substances, including anabolic steroids, buprenorphine, and ketamine, have less potential for abuse than a schedule I or II substance, have a currently accepted medical use, and have low or moderate risk of dependence if abused. Under the bill, manufacturing, distributing, or dispensing xylazine, or possessing with intent to manufacture, distribute, or dispense xylazine for illicit use is subject to criminal penalties under the CSA. The bill also requires xylazine transactions to be tracked in the drug reporting system maintained by the DEA. The bill exempts from registration under the CSA persons and entities that possess xylazine (1) lawfully dispensed by a veterinarian or pharmacy and (2) for an animal or for use in certain animal-control or wildlife programs. The bill also exempts xylazine manufacturers from the CSA's physical security requirements. Finally, the bill requires the DEA, in coordination with the Food and Drug Administration, to report on (1) the prevalence and impact of illicit xylazine use in the United States, and (2) updated information on the prevalence and proliferation of xylazine trafficking and misuse in the United States.

Sponsors

Bacon, Don
Cosponsor

Bacon, Don

Republican · NE-2 · B001298

Joined Feb 12, 2025
Website
N/A
Office
2104 Rayburn House Office Building
Balderson, Troy
Cosponsor

Balderson, Troy

Republican · OH-12 · B001306

Joined Feb 12, 2025
Website
N/A
Office
2429 Rayburn House Office Building
Carey, Mike
Cosponsor

Carey, Mike

Republican · OH-15 · C001126

Joined Feb 12, 2025
Website
N/A
Office
1433 Longworth House Office Building
Craig, Angie
Cosponsor

Craig, Angie

Democratic · MN-2 · C001119

Joined Feb 12, 2025
Website
N/A
Office
2052 Rayburn House Office Building
Crenshaw, Dan
Cosponsor

Crenshaw, Dan

Republican · TX-2 · C001120

Joined Feb 12, 2025
Website
N/A
Office
248 Cannon House Office Building
Pappas, Chris
Cosponsor

Pappas, Chris

Democratic · NH-1 · P000614

Joined Feb 12, 2025
Website
N/A
Office
452 Cannon House Office Building
Pfluger, August
Cosponsor

Pfluger, August

Republican · TX-11 · P000048

Joined Feb 12, 2025
Website
N/A
Office
2202 Rayburn House Office Building

Amendments

No amendment records are currently available for this bill.
Compiled bill record. Bill pages combine Congress.gov source payloads, normalized relationships, cached text analysis, vote links, and deterministic sector/signal extraction. This is not an official government record or legal advice; use the official source link when accuracy matters.